| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5605430 | International Journal of Cardiology | 2017 | 5 Pages |
Abstract
Sacubritil â valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mauro Gori, Maurizio Volterrani, Massimo Piepoli, Michele Senni,